Loading
Every dated change on the records linked to HER2-positive gastric cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Higher response rate and longer progression-free survival with pembrolizumab added to trastuzumab and chemotherapy, with benefit concentrated in PD-L1-positive tumours; accelerated approval in May 2021, later limited to PD-L1 combined positive score of 1 or more.
A milestone in how this cancer is treated.
Higher objective response rate and longer overall survival with trastuzumab deruxtecan than with irinotecan or paclitaxel; approved in January 2021.
A milestone in how this cancer is treated.
Trastuzumab emtansine did not improve overall survival over taxane chemotherapy in previously treated HER2-positive gastric cancer.
A milestone in how this cancer is treated.